#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Non-neoplastic portal vein thrombosis


Authors: D. Kamenář;  J. Špičák
Authors‘ workplace: Přednosta: prof. MUDr. Julius Špičák, CSc. ;  Klinika hepatogastroenterologie IKEM, Praha
Published in: Prakt. Lék. 2023; 103(1): 3-9
Category: Various Specialization

Overview

Non-neoplastic portal vein thrombosis causes partial or complete occlusion of the portal vein or its branches with all the hemodynamic consequences. It is essential to distinguish between patients with portal vein thrombosis without preexisting liver disease arising from a prothrombotic state and/or local factor, and patients with portal vein thrombosis complicating liver cirrhosis. Earlier diagnosis by more acceccible imaging modalities, and thus earlier initiation of effective anticoagulation, significantly improved the prognosis of noncirrhotic patients. Achieving recanalization of portal vein in patients with liver cirrhosis indicated for liver transplantation will enable or facilitate the transplantation itself.

Keywords:

portal vein thrombosis – portal hypertension – anticoagulation therapy – portal cholangiopathy – prothrombotic states


Sources

1. Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 2019; 156(6): 1582–1599.e1.

2. Sarin SK, Sollano JD, Chawla YK, et al. Members of the APASL working party on portal hypertension. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006; 26(5): 512–519.

3. Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31(3): 587–591.

4. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41(3): 603–608.

5. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology 2010; 51(1): 210–218.

6. Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: A meta-analysis. Blood 2012; 120(25): 4921–4928.

7. Peniket AJ. The myeloproliferative disorders. CPD Bull Cell Pathol 2002; 4(1): 35–38.

8. Turon F, Cervantes F, Colomer D, et al. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J Hepatol 2015; 62(1): 72–74.

9. Qi X, De Stefano V, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: A systematic review and meta–analysis of observational studies. J Gastroenterol Hepatol 2013; 28(3): 432–442.

10. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis: A meta-analysis. Thromb Haemost 2008; 99(4): 675–682.

11. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295–306.

12. Levine J, Branch D, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346(10): 752–763.

13. Qi X, De Stefano V, Su C, et al. Associations of antiphospholipid antibodies with splanchnic vein thrombosis: A systematic review with meta-analysis. Med (United States) 2015; 94(4).

14. Landman C, Nahon S, Cosnes J, et al. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(3).

15. Rebours V, Boudaoud L, Vullierme MP, et al. Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia. Am J Gastroenterol 2012; 107(10): 1579–1585.

16. Condat B, Pessione F, Denninger H, et al. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32(3): 466–470.

17. Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): Diagnosis and management in the modern era. Clin Infect Dis 1995; 21(5): 1114–1120.

18. Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010; 42(3): 163–170.

19. Elkrief L, Corcos O, Bruno O, et al. Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis. Liver Int 2014; 34(9): 1314–1321.

20. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: Risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120(2): 490–497.

21. Orr DW, Harrison PM, Devlin J, et al. Chronic Mesenteric Venous Thrombosis: Evaluation and Determinants of Survival During Long-Term Follow-up. Clin Gastroenterol Hepatol 2007; 5(1): 80–86.

22. Chawla Y, Dilawari JB. Anorectal varices – Their frequency in cirrhotic and non-cirrhotic portal hypertension. Gut 1991; 32(3): 309–311.

23. Handa P, Crowther M, Douketis JD. Portal vein thrombosis: A clinician–oriented and practical review. Clin Appl Thromb 2014; 20(5): 498–506.

24. Mínguez B, García-Pagán JC, Bosch J, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology 2006; 43(4): 707–714.

25. Dhiman RK, Behera A, Chawla YK, et al. Portal hypertensive biliopathy. Gut 2007; 56(7): 1001–1008.

26. Condat B, Vilgrain V, Asselah T, et al. Portal cavernoma-associated cholangiopathy: A clinical and MR cholangiography coupled with MR portography imaging study. Hepatology 2003; 37(6): 1302–1308.

27. Llop E, De Juan C, Seijo S, et al. Portal cholangiopathy: Radiological classification and natural history. Gut 2011; 60(6): 853–860.

28. Bradbury MS, Kavangh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. Radiographics 2002; 22(3): 527–541.

29. de Gaetano AM, Lafortune M, Patriquin, et al. Cavernous transformation of the portal vein: Patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. Am J Roentgenol 1995; 165(5): 1151–1155.

30. Vilgrain V, Condat B, Bureau C, et al. Atrophy-hypertrophy complex in patients with cavernous transformation of the portal vein: CT evaluation. Radiology 2006; 241(1): 149–155.

31. Garcia-Pagán JC, Buscarini E, Janssen HLA, et al. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64(1): 179–202.

32. Morasch MD, Ebaugh JL, Chiou AC, et al. Mesenteric venous thrombosis: A changing clinical entity. J Vasc Surg 2001; 34(4): 680–684.

33. Schoots IG, Koffeman GI, Legemate DA, et al. Systematic review of survival after acute mesenteric ischaemia according to disease aetiology. Br J Surg 2004; 91(1): 17–27.

34. Abdu RA, Zakhour BJ, Dallis DJ. Mesenteric venous thrombosis – 1911 to 1984. Surgery 1987; 101(4): 383–388.

35. Spaander MCW, Hoekstra J, Hansen BE, et al. Anticoagulant therapy in patients with non–cirrhotic portal vein thrombosis: Effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost 2013; 11(3): 452–459.

36. Ferreira CN, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology 2016; 63(5): 1640–1650.

37. Turnes J, García-Pagán JC, González M, et al. Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. Clin Gastroenterol Hepatol 2008; 6(12): 1412–1417.

38. De Franchis R. Abraldes JG, Bajaj J, et al. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63(3): 543–545.

39. Kanellopoulou T, Alexopoulou A, Theodossiades G, et al. Pylephlebitis: An overview of non–cirrhotic cases and factors related to outcome. Scand J Infect Dis 2010; 42(11–12): 804–811.

40. Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007; 102(11): 2464–2470.

41. Spaander MCW, Murad SD, van Buuren HR, et al. Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc 2008; 67(6): 821–827.

42. Sarin SK, Gupta N, Jha SK, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010; 139(4).

43. Hall TC, Garcea G, Metcalfe M, et al. Management of acute non-cirrhotic and non-malignant portal vein thrombosis: A systematic review. World J Surg 2011; 35(11): 2510–2520.

44. Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005; 16(5): 651–661.

45. Fanelli F, Angeloni S, Salvatori FM, et al. Transjugular intrahepatic portosystemic shunt with expanded–polytetrafuoroethylene- covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis 2011; 43(1): 78–84.

46. Luo X, Nie L, Zhou B, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. Gastroenterol Res Pract 2014; 2014: 659726.

47. Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 2011; 54(1): 78–88.

48. Kumar S, Sarr M, Kamath P. Mesenteric venous thrombosis. N Engl J Med 2001; 345(23): 1683–1688.

49. Khanna R, Sarin SK. Non-cirrhotic portal hypertension – Diagnosis and management. J Hepatol 2014; 60(2): 421–441.

50. Ögren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23796 consecutive autopsies. World J Gastroenterol 2006; 12(13): 2115–2119.

51. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012; 57(1): 203–212.

52. Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology 2015; 61(2): 660–667.

53. Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: Predictive factors and long-term outcomes. Am J Gastroenterol 2013; 108(4): 568–574.

54. Tripodi A, Mannucci PM. The Coagulopathy of Chronic Liver Disease. N Engl J Med 2011; 365(2): 147–156.

55. Wu X, Yao Z, Zhao L, et al. Phosphatidylserine on blood cells and endothelial cells contributes to the hypercoagulable state in cirrhosis. Liver Int 2016; 36(12): 1800–1810.

56. Zuwała-Jagiełło J, Simon KA, Pazgan-Simon M. Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report. Clin Exp Hepatol 2015; 1(3): 105–111.

57. Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51(4): 682–689.

58. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40(5): 736–741.

59. D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38(3): 599–612.

60. Tublin ME, Dodd GD, Baron RL. Benign and malignant portal vein thrombosis: Differentiation by CT characteristics. Am J Roentgenol 1997; 168(3): 719–723.

61. Rossi S, Rosa L, Ravetta V, et al. Contrast-enhanced versus conventional and color doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. Am J Roentgenol 2006; 186(3): 763–773.

62. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation. Gut 2005; 54(5): 691–697.

63. Englesbe MJ, Schaubel DE, Cai S, et al. Portal vein thrombosis and liver transplant survival benefit. Liver Transplant 2010; 16(8): 999–1005.

64. Rodríguez-Castro KI, Porte RJ, Nadal E, et al. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: A systematic review. Transplantation 2012; 94(11): 1145–1153.

65. Hibi T, Nishida S, Levi DM, et al. When and why portal vein thrombosis matters in liver transplantation: A critical audit of 174 cases. Ann Surg 2014; 259(4): 760–766.

66. Vianna RM, Mangus RS, Fridell JA, et al. Multivisceral transplantation for diffuse portomesenteric thrombosis. Ann Surg 2012; 255(6): 1144–1150.

67. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation. Gut 2005; 54(5): 691–697.

68. Delgado MG, Seijo S, Yepes I, et al. Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol 2012; 10(7): 776–783.

69. Rodriguez-Castro KI, Vitale A, Fadin M, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31(1): 34–42.

70. Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology 2017; 153(2): 480–487.

71. Garcia-Pagán JC, Buscarini E, Janssen HLA, et al. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64(1): 179–202.

72. Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143(5): 1253–1260.e4.

73. Senzolo M, Rodriguez-Castro KI, Rossetto V, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10(9): 1823–1829.

74. Weinberg EM, Palecki J, Reddy KR. Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis–Associated Portal Vein Thrombosis. Semin Liver Dis 2019; 39(2): 195–208.

75. Perarnau JM, Baju A, D’alteroche L, et al. Feasibility and longterm evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol 2010; 22(9): 1093–1098.

76. Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23(6): 767–775.

Labels
General practitioner for children and adolescents General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#